HomeFull speed ahead. Keep track of advancements in every frontier
Orforglipron (Foundayo)Eli Lilly—Tirzepatide (Mounjaro / Zepbound)Eli Lilly—RetatrutideEli Lilly—Orforglipron (Foundayo)Eli Lilly—VERVE-102 (PCSK9 base editor)Eli Lilly—RetatrutideEli Lilly—RetatrutideEli Lilly—Eli Lilly—Orforglipron (Foundayo)Eli Lilly—

Retatrutide

by Eli LillyUS

DeployStage 4 of 5

Phase 3 trials reading out well in 2026; FDA filing expected next.

Updated 25d agoChecked 25 Sep0 updates this week

Milestones

Next · Filing for obesity approval
  1. Phase 2 results in NEJM (24.2% at 48 weeks)Jun 2023Complete.
  2. Obesity + knee arthritis trial headlineDec 2025Complete.
  3. Phase 3 headline: 28.3% at 80 weeks (top dose)21 May 2026Complete.
  4. Filing for obesity approvalNowCurrent milestone.

Most important updates

  • 25d ago
  • 12 Aug 2026
  • 21 May 2026

Upcoming

  1. Q4 2026Retatrutide obesity NDA submission (next)

Physics limits

  • The body defends its weightAs weight falls, hunger hormones rise and energy use drops, so loss plateaus after about a year. When treatment stops, most people regain much of it: in one trial, about two-thirds within a year.
  • Part of the weight lost is muscleRoughly a quarter to a third of the weight lost on these drugs is lean mass, not fat. In older people that loss of muscle and bone can matter more than the weight itself.
  • Glucagon is a double-edged signalGlucagon burns energy but also raises blood sugar and heart rate. Balancing it against the other two hormones sets a ceiling on how hard the drug can push without side effects.

How it works

3 parts
A fatty liver under the microscope (white fat droplets): the liver fat retatrutide's glucagon signal helps burn off
A fatty liver under the microscope (white fat droplets): the liver fat retatrutide's glucagon signal helps burn offPhoto: Nephron · CC BY-SA 3.0 (opens commons.wikimedia.org)
Molecule

One peptide, three hormones

Retatrutide switches on the GIP, GLP-1 and glucagon receptors at once, and lasts long enough for weekly shots.

Appetite

Eat less

The GLP-1 and GIP signals act on the brain's appetite centres and slow the stomach, so people feel full sooner.

Burn

Spend more

The glucagon signal makes the liver burn fat and raises energy use, adding to weight loss and cutting liver fat.

Update log

3 updates

Tue 15 Sep

  • Major: PressTest

Wed 12 Aug

  • Minor: PressRegulatory

Thu 21 May

  • Major: PressTest

About Eli Lilly

The team behind Retatrutide

Eli Lilly

Zepbound, obesity pill, retatrutide

US drugmaker that leads in obesity and diabetes drugs. Tirzepatide (Mounjaro, Zepbound) is among the world's best-selling drugs, its GLP-1 pill was approved in 2026, and retatrutide gave about 28% weight loss in Phase 3. It bought Verve (gene editing) in 2025.

  • Became the first drugmaker worth about $1 trillion (Nov 2025), thanks to tirzepatide.
  • Foundayo (orforglipron), a daily GLP-1 pill with no food or water rules, was FDA-approved for obesity on 1 Apr 2026.
  • Retatrutide gave 28.3% average weight loss at 80 weeks on the top dose in Phase 3 (May 2026).
Founded
1876150 yrs
Headquarters
United States
Status
Public
Valuation
$1.1Tmarket capSep 2026
Works in
BiotechObesity & metabolism
Coverage
4 programs · 18 updateslatest 25d agochecked 25 Sep
People
David A. Ricks (opens en.wikipedia.org)Chair and CEODaniel SkovronskyChief Scientific Officer
Primer